Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.46 USD | -2.26% | -3.08% | +133.78% |
May. 02 | Transcript : Cardiff Oncology, Inc., Q1 2024 Earnings Call, May 02, 2024 | |
May. 02 | Cardiff Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Therapies for Cancers
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +26.42% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +26.42% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Mark Erlander
CEO | Chief Executive Officer | 64 | 13-03-03 |
James Levine
DFI | Director of Finance/CFO | 53 | 21-07-11 |
Tod Smeal
CTO | Chief Tech/Sci/R&D Officer | 59 | 22-01-10 |
Chief Tech/Sci/R&D Officer | - | 23-01-30 | |
Vicki Kelemen
COO | Chief Operating Officer | - | 14-12-31 |
Charles Monahan
LAW | General Counsel | - | 22-01-10 |
Brigitte Lindsay
PRN | Corporate Officer/Principal | - | 11-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
James Armitage
BRD | Director/Board Member | 77 | 20-04-21 |
Gary Pace
BRD | Director/Board Member | 76 | 20-04-21 |
Mark Erlander
CEO | Chief Executive Officer | 64 | 13-03-03 |
Lâle White
BRD | Director/Board Member | 68 | 20-04-21 |
Mani Mohindru
BRD | Director/Board Member | 52 | 21-06-09 |
Rodney Markin
CHM | Chairman | 67 | 14-02-18 |
Renee Tannenbaum
BRD | Director/Board Member | 72 | 21-06-09 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 44,724,591 | 41,348,436 ( 92.45 %) | 0 | 92.33 % |
Stock B | 0 | 60,600 | 0 | 0 |
Company contact information
Cardiff Oncology, Inc.
11055 Flintkote Avenue
92121, San Diego
+858 952 7570
http://www.cardiffoncology.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+133.78% | 155M | |
+64.23% | 62.59B | |
-2.31% | 41.18B | |
+43.91% | 40.29B | |
-8.29% | 27.9B | |
+11.97% | 26.21B | |
-21.16% | 19.09B | |
+7.54% | 13.08B | |
+27.17% | 12.05B | |
+25.72% | 12.26B |
- Stock Market
- Equities
- CRDF Stock
- Company Cardiff Oncology, Inc.